SEARCH:   Advanced

Blood, 2 April 2009, Vol. 113, No. 14, pp. 3307-3313. Prepublished online as a Blood First Edition Paper on September 3, 2008; DOI 10.1182/blood-2008-03-148874. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2008-03-148874v1 113/14/3307    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ribrag, V. Articles by Salles, G. Search for Related Content PubMed PubMed Citation Articles by Ribrag, V. Articles by Salles, G. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 31, 2008 Accepted July 18, 2008 Pharmacogenetic study in Hodgkin's lymphomas reveals the impact of UGT1A1 polymorphisms on patient's prognosis Vincent Ribrag*, Serge Koscielny, Olivier Casasnovas, Cecile Cazeneuve, Pauline Brice, Franck Morschhauser, Jean Gabarre, Aspasia Stamatoullas, Gilbert Lenoir, and Gilles Salles Labatoire de recherche translationnelle, Insitut Gustave Roussy, Villejuif, France Departement de statistiques, Institut Gustave Roussy, Villejuif, France Hopital Le Bocage, Dijon, France Labatoire de genetique, Institut Gustave Roussy, Villejuif, France Hopital Saint Louis, Paris, France Centre Hospitalier universitaire de Lille, Lille, France Hopital Pitie-Salpetriere, Paris, France Centre Henri Becquerel, Rouen, France Hospices Civils de Lyon, Universite de Lyon, UMR5139 du CNRS, Lyon, France * Corresponding author; email: ribrag{at}igr.fr. Hodgkin lymphoma is a highly curable malignancy, but treatment outcome might be influenced by inherited gene polymorphisms determining anticancer agent metabolism. We prospectively collected peripheral blood lymphocytes from 313 patients with Hodgkin lymphomas in order to analyze GSTP1, GSTM1, GSTT1, UGT1A1 and CYP3A4 enzyme gene polymorphisms. All patients were treated with chemotherapy, associated with radiotherapy when they had localized disease. There was no difference for GSTP1, GSTM1, GSTT1 as well as for UGT1A1 and CYP3A4 polymorphisms distributions between Hodgkin lymphoma patient and healthy control. Patients carrying one or 2 UGT1A1*28 allele had a significantly (P<.05) better FFP and FFTF than those homozygous for the UGT1A1 ‘TA6/TA6’ allele. Multivariate prognostic analyses showed that UGT1A1 polymorphism was as an independent prognostic parameter for all the studied end-points, the wild-type homozygous UGT1A1 ‘TA6/TA6’ genotype being associated with a significantly worse prognosis than genotypes with at least one UGT1A1*28 allele (OS; relative risk (RR)=2.54, 95% confidence interval (CI) (1.05 - 6.14); P=0.04; FFP, RR=2.70, CI (1.37 - 5.31); P=0.004; FFTF, RR: 2.37, CI (1.28 - 4.40), P=0.006). UGT1A1 polymorphism on TA repeats, that are thought to determine several anti-cancer drugs metabolism, influence Hodgkin's lymphoma patient's outcome. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020